HHMI
RMD icon

Howard Hughes Medical Institute’s ResMed RMD Stock Holding History

Howard Hughes Medical Institute’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-31
Closed -$7.47K – 392
2025
Q4 		$7.47K Hold
31
– – ﹤0.01% 267
2025
Q3 		$8.49K Hold
31
– – 0.01% 244
2025
Q2 		$8K Buy
+31
New +$7.39K ﹤0.01% 243

Other funds holding RMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $147M AUM 25.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Howard Hughes Medical Institute's RMD Position: Q1 2026 in Review

Howard Hughes Medical Institute sold out of ResMed (RMD) in Q1 2026, closing a stake of 31 shares — an estimated $7.47K sold.

Howard Hughes Medical Institute first reported a position in RMD in Q2 2025 and held it in 3 quarters. The position peaked at $8.49K in Q3 2025. 939 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

  • Howard Hughes Medical Institute reported no remaining ResMed position as of Q1 2026 after selling out during the quarter.
  • Howard Hughes Medical Institute sold 31 ResMed shares in Q1 2026, an estimated $7.47K.
  • Howard Hughes Medical Institute first reported a position in ResMed in Q2 2025 and held it in 3 quarters.
  • Howard Hughes Medical Institute's ResMed position peaked at $8.49K in Q3 2025.
  • 939 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on Howard Hughes Medical Institute's 13F filing for Q1 2026, filed 15 May 2026.